Difference between revisions of "Malignant solid neoplasm, ERBB2-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(44 intermediate revisions by 3 users not shown)
Line 1: Line 1:
−
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
+
<span id="BackToTop"></span>
−
 
+
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
−
<!--Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].-->
+
[[#top|Back to Top]]
−
 
+
</div>
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
Line 9: Line 9:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
 
−
'''Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.'''
 
 
=All lines of therapy=
 
=All lines of therapy=
−
==Ado-trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}}==
 
−
{| class="wikitable" style="float:right; margin-left: 5px;"
 
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
−
===Regimen {{#subobject:9b61eb|Variant=1}}===
 
−
{| class="wikitable" style="width: 100%; text-align:center;"
 
−
!style="width: 50%"|Study
 
−
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
−
|-
 
−
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9777 Li et al. 2018 (MSK 15-335)]
 
−
|style="background-color:#ffffbe"|Phase II basket trial, <20 pts reported to date
 
−
|-
 
−
|}
 
−
''Note: only partial results have been published to date.''
 
−
====Chemotherapy====
 
−
*[[Ado-trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1
 
−
 
−
'''21-day cycles'''
 
−
 
−
===References===
 
−
# '''MSK 15-335:''' Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. Epub 2018 Jul 10. [http://ascopubs.org/doi/full/10.1200/JCO.2018.77.9777 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29989854 PubMed]
 
−
 
 
==Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}==
 
==Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}==
−
{| class="wikitable" style="float:right; margin-left: 5px;"
+
<div class="toccolours" style="background-color:#eeeeee">
−
|-
 
−
|[[#top|back to top]]
 
−
|}
 
 
===Regimen {{#subobject:d9f619|Variant=1}}===
 
===Regimen {{#subobject:d9f619|Variant=1}}===
−
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 50%"|Study
+
!style="width: 33%"|Study
−
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ Hyman et al. 2018 (SUMMIT)]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ Hyman et al. 2018 (SUMMIT<sub>HER</sub>)]
 +
|NR to 2016-12-16
 
|style="background-color:#91cf61"|Non-randomized basket trial
 
|style="background-color:#91cf61"|Non-randomized basket trial
 
|-
 
|-
 
|}
 
|}
−
''Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length.''
+
''Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.''
−
====Eligibility criteria====
+
<div class="toccolours" style="background-color:#fdcdac">
−
*HER2 or HER3 mutations
+
====Biomarker eligibility criteria====
−
====Chemotherapy====
+
*Gene: HER2
−
*[[Neratinib (Nerlynx)]] 240 mg PO once per day
+
*Alteration: various [[Biomarkers#Substitution|substitutions]], [[Biomarkers#Insertion|insertions]], [[Biomarkers#Frameshift|frameshifts]], or [[Biomarkers#Structural variant|structural variants]]
−
====Supportive medications====
+
*Acceptable methods of measurement: next-generation sequencing assay or RT-PCR, Sanger, pyrosequencing, or mass spectrometry-based sequencing methods
 +
====Prior treatment criteria====
 +
* No prior treatment with HER kinase inhibitors
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Targeted therapy====
 +
*[[Neratinib (Nerlynx)]] 240 mg PO once per day on days 1 to 28
 +
 
 +
====Supportive therapy====
 
*[[Loperamide (Imodium)]] (dose not specified) mandatory during cycle 1
 
*[[Loperamide (Imodium)]] (dose not specified) mandatory during cycle 1
−
 
 
'''28-day cycles'''
 
'''28-day cycles'''
−
 
+
</div></div>
 
===References===
 
===References===
−
# '''SUMMIT:''' Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. [https://www.nature.com/articles/nature25475 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29420467 PubMed]
+
# '''SUMMIT:''' Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. [https://www.nature.com/articles/nature25475 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808581/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29420467/ PubMed] [https://clinicaltrials.gov/study/NCT01953926 NCT01953926]
  
 
==Pertuzumab & Trastuzumab {{#subobject:e0d17a|Regimen=1}}==
 
==Pertuzumab & Trastuzumab {{#subobject:e0d17a|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen {{#subobject:392a4b|Variant=1}}===
 
===Regimen {{#subobject:392a4b|Variant=1}}===
−
{| class="wikitable" style="width: 100%; text-align:center;"  
+
{| class="wikitable sortable" style="width: 60%; text-align:center;"  
−
!style="width: 50%"|Study
+
!style="width: 33%"|Study
−
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)]
+
|[https://doi.org/10.1200/JCO.2017.75.3780 Hainsworth et al. 2018 (MyPathway)]
−
|style="background-color:#91cf61"|Phase IIa
+
|2014-2016
 +
|style="background-color:#91cf61"|Phase 2a
 
|-
 
|-
 
|}
 
|}
−
====Eligibility criteria====
+
<div class="toccolours" style="background-color:#fdcdac">
−
*HER2 amplification or activating mutations
+
====Biomarker eligibility criteria====
−
====Chemotherapy====
+
*Gene: HER2
 +
*Alteration: [[Biomarkers#Amplification|amplification]] or [[Biomarkers#Activating|activation]] (including exon 20 [[Biomarkers#Insertion|insertions]], [[Biomarkers#Deletion|deletions]] around amino acids 755 to 759, and nonsynonymous amino acid [[Biomarkers#Substitution|substitutions]])
 +
*Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Targeted therapy====
 
*[[Pertuzumab (Perjeta)]] as follows:
 
*[[Pertuzumab (Perjeta)]] as follows:
 
**Cycle 1: 840 mg IV once on day 1
 
**Cycle 1: 840 mg IV once on day 1
−
**Cycle 2 onwards: 240 mg IV once on day 1
+
**Cycle 2 onwards: 420 mg IV once on day 1
 
*[[Trastuzumab (Herceptin)]] as follows:
 
*[[Trastuzumab (Herceptin)]] as follows:
 
**Cycle 1: 8 mg/kg IV once on day 1
 
**Cycle 1: 8 mg/kg IV once on day 1
 
**Cycle 2 onwards: 6 mg/kg IV once on day 1
 
**Cycle 2 onwards: 6 mg/kg IV once on day 1
 +
'''21-day cycles'''
 +
</div></div>
  
 +
===References===
 +
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312/ PubMed] [https://clinicaltrials.gov/study/NCT02091141 NCT02091141]
 +
##'''Update:''' Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024 Jan 20;42(3):258-265. Epub 2023 Oct 4. [https://doi.org/10.1200/jco.22.02636 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37793085/ PubMed]
 +
 +
==Trastuzumab deruxtecan monotherapy {{#subobject:dtxda41|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:dxd3eb|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10730032/ Meric-Bernstam et al. 2023 (DESTINY-PanTumo02)]
 +
|2020-10-07 to 2022-07-07
 +
| style="background-color:#91cf61" |Phase 2 (RT)
 +
|-
 +
|}
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Antibody-drug conjugate therapy====
 +
*[[Trastuzumab deruxtecan (Enhertu)]] 5.4 mg/kg IV once on day 1
 
'''21-day cycles'''
 
'''21-day cycles'''
 +
</div></div>
 +
===References===
 +
#'''DESTINY-PanTumor02:''' Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. Epub 2023 Oct 23. [https://doi.org/10.1200/jco.23.02005 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10730032/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/37870536/ PubMed] [https://clinicaltrials.gov/study/NCT04482309 NCT04482309]
  
 +
==Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}}==
 +
<div class="toccolours" style="background-color:#eeeeee">
 +
===Regimen {{#subobject:9b61eb|Variant=1}}===
 +
{| class="wikitable sortable" style="width: 60%; text-align:center;"
 +
!style="width: 33%"|Study
 +
!style="width: 33%"|Dates of enrollment
 +
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366814/ Li et al. 2018 (MSK 15-335)]
 +
|2016-03 to 2016-12
 +
|style="background-color:#ffffbe"|Phase 2 basket trial, fewer than 20 pts reported to date
 +
|-
 +
|}
 +
''Note: only partial results have been published to date.''
 +
<div class="toccolours" style="background-color:#fdcdac">
 +
====Biomarker eligibility criteria====
 +
*Gene: HER2
 +
*Alteration: various exon 20 [[Biomarkers#Insertion|insertions]], single-base pair [[Biomarkers#Substitution|substitutions]], or other likely [[Biomarkers#Activation|activating]] mutations
 +
*Acceptable methods of measurement: next-generation sequencing
 +
</div>
 +
<div class="toccolours" style="background-color:#b3e2cd">
 +
====Antibody-drug conjugate therapy====
 +
*[[Trastuzumab emtansine (Kadcyla)]] 3.6 mg/kg IV once on day 1
 +
'''21-day cycles'''
 +
</div></div>
 
===References===
 
===References===
−
# '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.3780 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29320312 PubMed]
+
# '''MSK 15-335:''' Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. Epub 2018 Jul 10. [https://doi.org/10.1200/JCO.2018.77.9777 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6366814/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/29989854/ PubMed] [https://clinicaltrials.gov/study/NCT02675829 NCT02675829]
−
 
+
[[Category:Malignant solid neoplasm, ERBB2-mutated regimens]]
−
[[Category:ERBB2 (HER2) regimens]]
 
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
−
[[Category:Site-agnostic regimens]]
+
[[Category:Malignant solid neoplasm]]

Revision as of 00:11, 20 April 2024

Back to Top

4 regimens on this page
4 variants on this page


All lines of therapy

Neratinib monotherapy

Regimen

Study Dates of enrollment Evidence
Hyman et al. 2018 (SUMMITHER) NR to 2016-12-16 Non-randomized basket trial

Note: the cycle length is not described in the manuscript; the authors have clarified that the cycles are 28 days in length. This trial should not be confused with the one by the same name in multiple myeloma.

Biomarker eligibility criteria

Prior treatment criteria

  • No prior treatment with HER kinase inhibitors

Targeted therapy

Supportive therapy

28-day cycles

References

  1. SUMMIT: Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194. Epub 2018 Jan 31. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01953926

Pertuzumab & Trastuzumab

Regimen

Study Dates of enrollment Evidence
Hainsworth et al. 2018 (MyPathway) 2014-2016 Phase 2a

Biomarker eligibility criteria

  • Gene: HER2
  • Alteration: amplification or activation (including exon 20 insertions, deletions around amino acids 755 to 759, and nonsynonymous amino acid substitutions)
  • Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy

Targeted therapy

  • Pertuzumab (Perjeta) as follows:
    • Cycle 1: 840 mg IV once on day 1
    • Cycle 2 onwards: 420 mg IV once on day 1
  • Trastuzumab (Herceptin) as follows:
    • Cycle 1: 8 mg/kg IV once on day 1
    • Cycle 2 onwards: 6 mg/kg IV once on day 1

21-day cycles

References

  1. MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141
    1. Update: Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024 Jan 20;42(3):258-265. Epub 2023 Oct 4. link to original article PubMed

Trastuzumab deruxtecan monotherapy

Regimen

Study Dates of enrollment Evidence
Meric-Bernstam et al. 2023 (DESTINY-PanTumo02) 2020-10-07 to 2022-07-07 Phase 2 (RT)

Antibody-drug conjugate therapy

21-day cycles

References

  1. DESTINY-PanTumor02: Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan 1;42(1):47-58. Epub 2023 Oct 23. link to original article link to PMC article contains dosing details in abstract PubMed NCT04482309

Trastuzumab emtansine monotherapy

Regimen

Study Dates of enrollment Evidence
Li et al. 2018 (MSK 15-335) 2016-03 to 2016-12 Phase 2 basket trial, fewer than 20 pts reported to date

Note: only partial results have been published to date.

Biomarker eligibility criteria

  • Gene: HER2
  • Alteration: various exon 20 insertions, single-base pair substitutions, or other likely activating mutations
  • Acceptable methods of measurement: next-generation sequencing

Antibody-drug conjugate therapy

21-day cycles

References

  1. MSK 15-335: Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. Epub 2018 Jul 10. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02675829
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_solid_neoplasm,_ERBB2-mutated&oldid=84907"